Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. By Keane et al. 2015 

Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. By Ludwig et al. 2015

Key sentence from the paper: “…the PCa patients in the ADT group performed significantly worse than those of age- and education-matched patients in the non-ADT group and [healthy controls] on the neuropsychological tests assessing memory, attention and information processing, indicating ADT impaired cognition in Chinese PCa patients...”

Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. By Nguyen et al. 2015

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. By McKay et al. 2015 

Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. By Gunnarsson et al. 2015 

A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). By Stefanopoulou et al. 2015 

Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. By Tsai et al. 2015 

"First, do no harm": Managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer. By Lomax et al. 2015

The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment. By Li et al. 2015